Stay updated on Safety of Selonsertib, Firsocostat, & Cilofexor in NASH Clinical Trial
Sign up to get notified when there's something new on the Safety of Selonsertib, Firsocostat, & Cilofexor in NASH Clinical Trial page.

Latest updates to the Safety of Selonsertib, Firsocostat, & Cilofexor in NASH Clinical Trial page
- CheckyesterdayChange DetectedNAFLD is added as a related topic and MedlinePlus Genetics is listed as a related topic; the page revision is updated from v3.3.3 to v3.3.4.SummaryDifference0.2%

- Check8 days agoChange DetectedRemoved the NAFLD topic tag and the related MedlinePlus Genetics topic from the page's topics.SummaryDifference0.1%

- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedThe page now uses a general 'Locations' link instead of listing specific state locations (Arizona, California, Florida, Louisiana, Tennessee, Texas). It also adds 'Non-alcoholic fatty liver disease' and MedlinePlus Genetics as topics.SummaryDifference0.7%

- Check30 days agoChange DetectedThe page no longer lists the core condition 'Non-alcoholic fatty liver disease' and related topics such as MedlinePlus Genetics.SummaryDifference0.1%

- Check37 days agoChange DetectedAdded related topics Non-alcoholic fatty liver disease and MedlinePlus Genetics in the Related Topics section.SummaryDifference0.1%

- Check44 days agoChange DetectedThe page content no longer includes the term 'Non-alcoholic fatty liver disease' and the related topic 'MedlinePlus Genetics'.SummaryDifference0.1%

Stay in the know with updates to Safety of Selonsertib, Firsocostat, & Cilofexor in NASH Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Safety of Selonsertib, Firsocostat, & Cilofexor in NASH Clinical Trial page.